SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE
GCT3013-02
Phase 2 small_molecule active
Quick answer
SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE for Lymphoma of B-cell origin is a Phase 2 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Genmab A/S
- Indication
- Lymphoma of B-cell origin
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active